Key result
Two patients treated with obinutuzumab for follicular lymphoma developed severe disseminated enteroviral infections presenting with hepatitis, edema, and a dermatomyositis-like syndrome, which rapidly improved with intravenous immunoglobulin therapy.
Case Report (n=2)
Clinicians should remain vigilant for atypical presentations of disseminated enteroviral infections in patients receiving obinutuzumab, which may respond to intravenous immunoglobulin.
May warrant vigilance for enteroviral infections with obinutuzumab; hypothesis-generating and requires prospective validation.
Two cases of disseminated enteroviral infection occurred in patients who received the CD20 monoclonal antibody obinutuzumab. Clinical features included hepatitis, edema, and a dermatomyositis-like syndrome. These manifestations may be unfamiliar to clinicians and are possibly responsive to intravenous immunoglobulin. Clinicians should remain vigilant for enteroviral infections in patients receiving obinutuzumab.
No takes yet. Share an insight, caveat, or question.
Dendle et al. (2015) conducted a case report in Follicular lymphoma (n=2). Obinutuzumab was evaluated on Disseminated enteroviral infection. Two patients treated with obinutuzumab for follicular lymphoma developed severe disseminated enteroviral infections presenting with hepatitis, edema, and a dermatomyositis-like syndrome, which rapidly improved with intravenous immunoglobulin therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: